Go Pro

Healthcare Stocks List

This page shows information about the 50 largest healthcare sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and Merck & Co., Inc..

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$1,168.98 -7.12 (-0.61%)
As of 03:58 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The company recently reported earnings per share significantly above analysts' expectations, indicating strong financial performance and potential for continued growth.
  • Eli Lilly and Co's revenue has shown impressive year-over-year growth, suggesting robust demand for its products and effective market strategies.
  • The current stock price is around $1,292, reflecting positive market sentiment and strong analyst ratings, with many recommending a buy.

Cons of Eli Lilly and Company

  • Despite strong earnings, the pharmaceutical industry is highly competitive, and Eli Lilly and Co may face challenges from new entrants and existing competitors.
  • The company's dividend yield is relatively low, which may not appeal to income-focused investors looking for higher returns from dividends.
  • Market volatility can impact stock prices, and any negative news regarding the company or the industry could lead to significant price fluctuations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$1.11 trillion
P/E Ratio
39.23
Consensus Rating
Moderate Buy
Consensus Price Target
$1,292.18 (+10.5% Upside)
Volume
2.45 million shares
Average Volume
2.87 million shares
Today's Range
$1,162.93
$1,180.00
50-Day Range
$1,103.69
$1,280.62
52-Week Range
$712.05
$1,292.65
Dividend Yield
0.59%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$268.30 +2.53 (+0.95%)
As of 03:58 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The current stock price is around $268, reflecting a strong market position and investor confidence.
  • Johnson & Johnson has a solid net margin of over 21%, indicating efficient management and profitability.
  • The company has consistently increased its quarterly dividend, with a recent announcement of $1.34 per share, showcasing its commitment to returning value to shareholders.

Cons of Johnson & Johnson

  • Despite positive growth, some analysts have downgraded their ratings, indicating potential concerns about future performance.
  • The company's dividend payout ratio is over 62%, which, while sustainable, may limit future growth investments.
  • Market volatility and economic uncertainties could impact the healthcare sector, affecting Johnson & Johnson's stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$640.48 billion
P/E Ratio
31.09
Consensus Rating
Moderate Buy
Consensus Price Target
$268.22 (-0.0% Downside)
Volume
5.76 million shares
Average Volume
6.50 million shares
Today's Range
$264.27
$268.38
50-Day Range
$231.12
$273.28
52-Week Range
$173.33
$276.47
Dividend Yield
2.02%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$256.08 -2.07 (-0.80%)
As of 03:58 PM Eastern

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • AbbVie recently reported earnings per share (EPS) of $3.65, exceeding expectations, which indicates strong financial performance and potential for growth.
  • The company has shown a year-over-year revenue increase of over 10%, suggesting robust demand for its products and effective business strategies.
  • AbbVie has a current stock price around $250, which may present a favorable entry point for investors looking for growth in the biopharmaceutical sector.

Cons of AbbVie

  • AbbVie has a negative return on equity of over 422%, which may raise concerns about the company's efficiency in generating profits from shareholders' equity.
  • The company's dividend payout ratio is currently at 195.48%, indicating that it is paying out more in dividends than it is earning, which could be unsustainable in the long term.
  • Recent insider selling, including a significant transaction by an executive vice president, may signal a lack of confidence in the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$456.10 billion
P/E Ratio
72.34
Consensus Rating
Moderate Buy
Consensus Price Target
$275.95 (+7.8% Upside)
Volume
3.22 million shares
Average Volume
4.98 million shares
Today's Range
$255.08
$259.00
50-Day Range
$230.10
$265.63
52-Week Range
$190.75
$267.47
Dividend Yield
2.68%
Merck & Co., Inc. stock logo

4. Merck & Co., Inc. NYSE:MRK

$148.30 -1.24 (-0.83%)
As of 03:58 PM Eastern

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • Merck has demonstrated strong revenue growth, with a recent quarterly revenue increase of over 5% compared to the same period last year, indicating robust business performance.
  • The company has set an earnings per share (EPS) guidance for FY 2026 between 2.660 and 2.760, suggesting a positive outlook for profitability.
  • Merck's current stock price is around $147.60, which reflects a consensus rating of "Moderate Buy" from analysts, indicating potential for price appreciation.

Cons of Merck & Co., Inc.

  • Merck's dividend payout ratio is currently at 272.00%, which is significantly high and may raise concerns about the sustainability of its dividend payments in the long term.
  • The company faces intense competition in the biopharmaceutical sector, particularly in oncology and vaccines, which could impact its market share and profitability.
  • Recent analyst ratings have shown mixed sentiments, with some firms maintaining a "neutral" rating, indicating uncertainty about future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$368.94 billion
P/E Ratio
118.64
Consensus Rating
Moderate Buy
Consensus Price Target
$147.60 (-0.5% Downside)
Volume
8.06 million shares
Average Volume
11.20 million shares
Today's Range
$145.75
$149.01
50-Day Range
$115.47
$156.54
52-Week Range
$77.58
$156.92
Dividend Yield
2.27%
UnitedHealth Group stock logo

5. UnitedHealth Group NYSE:UNH

$393.99 -1.06 (-0.27%)
As of 03:58 PM Eastern

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The company reported impressive earnings per share (EPS) of $6.38 for the latest quarter, significantly exceeding analyst expectations, which indicates strong financial performance and effective management.
  • UnitedHealth Group has a solid return on equity of 16.53%, suggesting that the company is efficient in generating profits from its equity investments, which is a positive sign for potential investors.
  • The current stock price is around $500, reflecting a stable investment opportunity in the healthcare sector, which is often considered resilient during economic fluctuations.

Cons of UnitedHealth Group

  • The company's net margin stands at 3.14%, which, while positive, may indicate that there is limited room for profit expansion compared to other sectors, potentially affecting long-term growth.
  • UnitedHealth Group's payout ratio is currently 59.72%, suggesting that a significant portion of earnings is being distributed as dividends, which could limit reinvestment in growth opportunities.
  • Despite recent revenue growth, the year-over-year increase was only 0.4%, indicating that the company may face challenges in maintaining momentum in a competitive healthcare market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$354.59 billion
P/E Ratio
25.35
Consensus Rating
Moderate Buy
Consensus Price Target
$456.56 (+15.9% Upside)
Volume
2.45 million shares
Average Volume
4.11 million shares
Today's Range
$392.66
$396.74
50-Day Range
$384.60
$436.19
52-Week Range
$255.96
$461.62
Dividend Yield
2.35%
Novartis stock logo

6. Novartis NYSE:NVS

$153.75 -0.90 (-0.58%)
As of 03:58 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • The company reported a strong earnings per share (EPS) of $2.41 for the latest quarter, indicating solid profitability and effective management of expenses.
  • Novartis AG has a robust net margin of over 23%, showcasing its ability to convert revenue into profit efficiently, which is attractive for investors seeking stable returns.
  • With a market capitalization of approximately $302.35 billion, Novartis AG is a major player in the pharmaceutical industry, providing a sense of stability and reliability for investors.

Cons of Novartis

  • The company has a debt-to-equity ratio of 0.89, which, while manageable, indicates that it has a significant amount of debt compared to its equity, potentially posing risks in economic downturns.
  • With a price-to-earnings (P/E) ratio of 23.90, the stock may be considered overvalued compared to its earnings, which could deter value-focused investors.
  • The current ratio of 0.86 suggests that Novartis AG may have difficulty meeting its short-term liabilities, which could raise concerns about liquidity.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$295.10 billion
P/E Ratio
23.19
Consensus Rating
Hold
Consensus Price Target
$141.20 (-8.2% Downside)
Volume
1.17 million shares
Average Volume
1.42 million shares
Today's Range
$152.77
$154.57
50-Day Range
$148.85
$160.39
52-Week Range
$121.57
$170.46
Dividend Yield
1.99%
Astrazeneca stock logo

7. Astrazeneca NYSE:AZN

$162.83 -1.69 (-1.03%)
As of 03:58 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Market Capitalization
$255.16 billion
P/E Ratio
24.34
Consensus Rating
Moderate Buy
Consensus Price Target
$206.67 (+26.9% Upside)
Volume
2.88 million shares
Average Volume
4.35 million shares
Today's Range
$161.18
$163.54
50-Day Range
$155.79
$194.96
52-Week Range
$145.79
$212.71
Dividend Yield
2.64%
Amgen stock logo

8. Amgen NASDAQ:AMGN

$432.42 -4.57 (-1.05%)
As of 04:00 PM Eastern

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • The current stock price is around $380, which is significantly lower than its one-year high, indicating potential for growth.
  • Amgen Inc. reported strong earnings recently, with earnings per share surpassing expectations, showcasing robust financial performance.
  • The company has a high return on equity, reflecting effective management and profitability, which can be attractive to investors.

Cons of Amgen

  • The company has a high debt-to-equity ratio, which may indicate financial risk and could affect its ability to invest in growth opportunities.
  • Amgen Inc. has a relatively high price-to-earnings (P/E) ratio, suggesting that the stock may be overvalued compared to its earnings.
  • With a beta of 0.41, the stock is less volatile than the market, which may limit potential gains during bullish market conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$236.25 billion
P/E Ratio
26.88
Consensus Rating
Hold
Consensus Price Target
$380.43 (-12.0% Downside)
Volume
1.74 million shares
Average Volume
2.59 million shares
Today's Range
$430.72
$437.89
50-Day Range
$344.72
$443.84
52-Week Range
$269.77
$447.03
Dividend Yield
2.31%
Thermo Fisher Scientific stock logo

9. Thermo Fisher Scientific NYSE:TMO

$621.87 -8.83 (-1.40%)
As of 03:58 PM Eastern

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • Thermo Fisher Scientific Inc. has a diverse portfolio that includes analytical instruments and laboratory equipment, which positions the company well in the growing life sciences market.
  • The company is actively involved in biopharma services, including contract development and manufacturing, which is crucial for pharmaceutical and biotechnology companies looking to streamline their operations.
  • Recent advancements in their laboratory information management and data-analysis software enhance operational efficiency for clients, making Thermo Fisher a valuable partner in research and clinical settings.

Cons of Thermo Fisher Scientific

  • Market competition in the analytical instruments and laboratory equipment sector is intense, which could pressure profit margins and market share.
  • Dependence on the pharmaceutical and biotechnology sectors means that any downturn in these industries could adversely affect Thermo Fisher's revenue streams.
  • Regulatory challenges in the healthcare industry can lead to increased operational costs and delays in product development, impacting overall performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$233.20 billion
P/E Ratio
33.45
Consensus Rating
Moderate Buy
Consensus Price Target
$619.41 (-0.4% Downside)
Volume
1.02 million shares
Average Volume
1.73 million shares
Today's Range
$617.45
$630.00
50-Day Range
$464.18
$634.48
52-Week Range
$435.27
$647.00
Dividend Yield
0.30%
Novo Nordisk A/S stock logo

10. Novo Nordisk A/S NYSE:NVO

$45.59 -0.67 (-1.45%)
As of 03:58 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • The current stock price is around $46, which is significantly lower than its twelve-month high, indicating potential for growth.
  • With a market capitalization of approximately $198.60 billion, Novo Nordisk is a major player in the pharmaceutical industry, particularly in diabetes care and metabolic health.
  • The company reported a strong net margin of over 35%, suggesting efficient management and profitability, which can lead to higher returns for investors.

Cons of Novo Nordisk A/S

  • The price-to-earnings (P/E) ratio is around 10.88, which may suggest that the stock is undervalued, but could also indicate market skepticism about future growth.
  • With a debt-to-equity ratio of 0.59, while manageable, it indicates that the company does carry some debt, which could be a concern in volatile markets.
  • Recent reports indicate that some analysts have issued "hold" ratings, suggesting that there may not be strong bullish sentiment in the short term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$206.55 billion
P/E Ratio
11.15
Consensus Rating
Hold
Consensus Price Target
$64.94 (+42.4% Upside)
Volume
8.50 million shares
Average Volume
14.81 million shares
Today's Range
$45.41
$46.21
50-Day Range
$44.16
$51.56
52-Week Range
$35.12
$64.16
Dividend Yield
1.76%
Abbott Laboratories stock logo

11. Abbott Laboratories NYSE:ABT

$112.63 +1.04 (+0.93%)
As of 03:58 PM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The company recently reported a quarterly revenue increase of 13.0% year-over-year, indicating strong growth and demand for its products.
  • Abbott Laboratories has set its guidance for Q3 2026 EPS between 1.380-1.46, suggesting confidence in continued profitability.
  • The current stock price is around $100, reflecting a stable investment opportunity in the healthcare sector.

Cons of Abbott Laboratories

  • Abbott agreed to a significant settlement of approximately $670 million related to litigation over its specialty formulas, which could impact future earnings.
  • The payout ratio is currently at 81.55%, indicating that a large portion of earnings is being distributed as dividends, which may limit reinvestment in growth opportunities.
  • Ongoing legal uncertainties related to infant formula products may pose risks to the company's reputation and financial stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$193.09 billion
P/E Ratio
36.45
Consensus Rating
Moderate Buy
Consensus Price Target
$119.50 (+6.1% Upside)
Volume
7.54 million shares
Average Volume
7.70 million shares
Today's Range
$111.11
$112.75
50-Day Range
$87.78
$116.70
52-Week Range
$81.97
$137.49
Dividend Yield
2.26%
Gilead Sciences stock logo

12. Gilead Sciences NASDAQ:GILD

$145.68 -3.18 (-2.14%)
As of 04:00 PM Eastern

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The company recently reported a quarterly revenue of approximately $7.80 billion, exceeding analysts' expectations, indicating strong financial performance.
  • Gilead Sciences, Inc. has a diverse product portfolio, particularly in antiviral therapies, which positions it well in the biopharmaceutical market.
  • The current stock price is around $131, reflecting a stable market presence and potential for growth.

Cons of Gilead Sciences

  • The company has a negative return on equity of 2.11%, which may raise concerns about its profitability and efficiency in generating returns for shareholders.
  • Gilead Sciences, Inc. has a high debt-to-equity ratio of 2.03, indicating a reliance on debt financing that could pose risks in a fluctuating market.
  • The firm reported a negative net margin of 10.64%, suggesting that it is currently operating at a loss, which could impact future profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$184.58 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$158.04 (+8.5% Upside)
Volume
3.95 million shares
Average Volume
6.47 million shares
Today's Range
$144.88
$149.47
50-Day Range
$123.84
$148.86
52-Week Range
$108.46
$157.29
Dividend Yield
2.20%
Pfizer stock logo

13. Pfizer NYSE:PFE

$27.95 -0.07 (-0.25%)
As of 03:58 PM Eastern

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • Pfizer Inc. recently reported earnings per share (EPS) of $0.77, exceeding analyst expectations, which indicates strong financial performance and potential for future growth.
  • The company has a solid revenue stream, with quarterly revenue reaching $15.03 billion, surpassing estimates, suggesting robust demand for its products.
  • Pfizer Inc. has set a favorable guidance for FY 2026, projecting EPS between 2.800 and 3.000, which may attract investors looking for growth opportunities.

Cons of Pfizer

  • The company's payout ratio is notably high at 226.32%, which may raise concerns about sustainability of dividend payments in the long term.
  • Recent analyst downgrades and reduced price targets from firms like JPMorgan and Bank of America indicate a cautious outlook on the stock's performance.
  • Pfizer Inc. has experienced a slight decline in EPS compared to the same quarter last year, which could signal potential challenges in maintaining growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$159.70 billion
P/E Ratio
36.78
Consensus Rating
Hold
Consensus Price Target
$28.28 (+1.2% Upside)
Volume
27.17 million shares
Average Volume
38.99 million shares
Today's Range
$27.77
$28.02
50-Day Range
$23.64
$28.53
52-Week Range
$23.58
$28.75
Dividend Yield
6.14%
Danaher stock logo

14. Danaher NYSE:DHR

$216.41 +0.73 (+0.34%)
As of 03:58 PM Eastern

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • The current stock price is around $216, which reflects a strong performance in the market and indicates potential for growth.
  • Danaher Co. has recently reported earnings that exceeded analysts' expectations, showcasing its ability to generate revenue effectively.
  • The company has a solid market capitalization of approximately $151.94 billion, indicating its stability and presence in the industry.

Cons of Danaher

  • The stock has experienced fluctuations, with a 52-week high of $242.80 and a low of $160.93, indicating potential volatility.
  • Despite recent earnings growth, the company's price-to-earnings ratio is relatively high, which may suggest that the stock is overvalued compared to its earnings.
  • Danaher Co. has a PEG ratio of 2.63, which indicates that its growth may not justify its current stock price, raising concerns about future returns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$151.62 billion
P/E Ratio
38.44
Consensus Rating
Moderate Buy
Consensus Price Target
$228.91 (+5.8% Upside)
Volume
2.86 million shares
Average Volume
3.43 million shares
Today's Range
$212.85
$217.04
50-Day Range
$178.22
$219.42
52-Week Range
$160.93
$242.80
Dividend Yield
0.74%
Vertex Pharmaceuticals stock logo

15. Vertex Pharmaceuticals NASDAQ:VRTX

$541.69 -5.86 (-1.07%)
As of 04:00 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The company reported strong quarterly revenue growth, with a year-over-year increase of 12.5%, indicating robust demand for its products.
  • Vertex Pharmaceuticals Incorporated has a solid return on equity of over 23%, suggesting effective management and profitability in generating returns for shareholders.
  • The current stock price is around $492, which may present a favorable entry point for investors looking to capitalize on the company's growth potential.

Cons of Vertex Pharmaceuticals

  • The company recently missed earnings estimates by a small margin, which could raise concerns about its ability to meet market expectations consistently.
  • Insider selling activity has been noted, with executives reducing their holdings, which may signal a lack of confidence in the stock's short-term performance.
  • Vertex Pharmaceuticals Incorporated has a relatively high P/E ratio of 31.90, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$138.97 billion
P/E Ratio
31.53
Consensus Rating
Moderate Buy
Consensus Price Target
$563.50 (+4.0% Upside)
Volume
886,802 shares
Average Volume
1.20 million shares
Today's Range
$540.08
$549.57
50-Day Range
$466.79
$552.85
52-Week Range
$374.17
$555.69
Dividend Yield
N/A
Bristol Myers Squibb stock logo

16. Bristol Myers Squibb NYSE:BMY

$66.62 -0.33 (-0.49%)
As of 03:58 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The current stock price is around $66, which is close to the consensus target price of $66.06, indicating potential for growth.
  • Recent ratings from analysts show strong support, with one analyst giving a "Strong Buy" rating and thirteen others issuing "Buy" ratings, suggesting confidence in the company's performance.
  • Bristol-Myers Squibb is focused on advancing therapies in critical areas such as oncology and immunology, which are high-demand fields in the biopharmaceutical market.

Cons of Bristol Myers Squibb

  • Some analysts have downgraded their ratings, with Jefferies Financial Group moving from a "Buy" to a "Hold," which may indicate concerns about the stock's short-term performance.
  • There is a significant number of analysts (ten) who have assigned a "Hold" rating, suggesting uncertainty about the stock's potential for immediate growth.
  • Market volatility can impact biopharmaceutical stocks, and any negative news regarding drug approvals or market competition could adversely affect Bristol-Myers Squibb's stock price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$136.76 billion
P/E Ratio
14.67
Consensus Rating
Moderate Buy
Consensus Price Target
$66.06 (-0.8% Downside)
Volume
5.54 million shares
Average Volume
11.01 million shares
Today's Range
$66.19
$66.84
50-Day Range
$54.66
$67.86
52-Week Range
$42.52
$68.64
Dividend Yield
3.76%
Intuitive Surgical stock logo

17. Intuitive Surgical NASDAQ:ISRG

$372.60 +5.53 (+1.51%)
As of 04:00 PM Eastern

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • Intuitive Surgical, Inc. has shown strong revenue growth, with a recent quarter reporting an 18.4% increase year-over-year, indicating robust demand for its products.
  • The company is a leader in robotic-assisted surgical systems, particularly known for its latest da Vinci surgical systems, which enhance precision and control in minimally invasive procedures.
  • Analysts have a consensus rating of "Moderate Buy" for the stock, suggesting positive sentiment among investment professionals regarding its future performance.

Cons of Intuitive Surgical

  • Recent analyst downgrades have seen price targets reduced significantly, with some analysts lowering their expectations for the stock's performance.
  • Despite strong revenue growth, the company faces increasing competition in the medical technology sector, which could impact its market share and profitability.
  • There is a potential risk associated with regulatory changes in the healthcare industry that could affect the approval and use of surgical technologies.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$129.68 billion
P/E Ratio
42.68
Consensus Rating
Moderate Buy
Consensus Price Target
$508.68 (+36.5% Upside)
Volume
1.80 million shares
Average Volume
2.62 million shares
Today's Range
$366.74
$373.40
50-Day Range
$332.02
$432.83
52-Week Range
$328.57
$603.88
Dividend Yield
N/A
Stryker stock logo

18. Stryker NYSE:SYK

$331.32 +9.20 (+2.86%)
As of 03:58 PM Eastern

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • Stryker Co. reported strong earnings of $3.69 per share, exceeding analysts' expectations, which indicates robust financial performance and potential for future growth.
  • The company has a solid revenue growth of approximately 9.4% year-over-year, reflecting increasing demand for its medical technologies and products.
  • With a return on equity of 23.63%, Stryker Co. demonstrates effective management and profitability, which can be attractive to investors looking for efficient capital use.

Cons of Stryker

  • Recent insider selling by a director, who sold 350,000 shares, may raise concerns about the company's future prospects and could signal a lack of confidence among insiders.
  • Analysts have noted execution risks, including potential cyber and supply-chain disruptions, which could impact the company's operational efficiency and profitability.
  • Some analysts have lowered their price targets for Stryker Co., indicating a cautious outlook and potential near-term pressure on the stock price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$123.56 billion
P/E Ratio
34.33
Consensus Rating
Moderate Buy
Consensus Price Target
$386.28 (+16.6% Upside)
Volume
2.23 million shares
Average Volume
2.35 million shares
Today's Range
$322.12
$332.72
50-Day Range
$304.64
$352.35
52-Week Range
$281.00
$396.86
Dividend Yield
1.09%
CVS Health stock logo

19. CVS Health NYSE:CVS

$93.15 +0.23 (+0.25%)
As of 03:58 PM Eastern

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. recently reported strong earnings, with an EPS of $2.58, significantly exceeding analysts' expectations, indicating robust financial performance.
  • The company has shown a year-over-year revenue increase of 7.3%, reflecting its growth potential and ability to expand its market share.
  • CVS Health Co. has a solid dividend yield of approximately 2.8%, providing investors with a steady income stream, which is attractive for income-focused investors.

Cons of CVS Health

  • The company's net margin is relatively low at 1.18%, which may indicate challenges in profitability compared to competitors.
  • CVS Health Co. has a dividend payout ratio of 70.37%, suggesting that a significant portion of earnings is being distributed as dividends, which could limit reinvestment in growth opportunities.
  • Despite positive earnings, the healthcare sector can be volatile and subject to regulatory changes, which may impact CVS Health Co.'s operations and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$118.84 billion
P/E Ratio
24.64
Consensus Rating
Moderate Buy
Consensus Price Target
$107.17 (+15.0% Upside)
Volume
3.99 million shares
Average Volume
7.84 million shares
Today's Range
$93.01
$93.93
50-Day Range
$92.88
$110.40
52-Week Range
$69.51
$110.68
Dividend Yield
2.86%
Medtronic stock logo

20. Medtronic NYSE:MDT

$91.28 +1.31 (+1.46%)
As of 03:58 PM Eastern

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The company recently reported earnings per share (EPS) of $1.55, exceeding analyst expectations, which indicates strong financial performance and potential for growth.
  • Medtronic plc achieved a revenue of $9.81 billion for the quarter, surpassing estimates, reflecting robust demand for its medical technology products.
  • The firm has set its fiscal year 2027 guidance at an EPS range of 5.900-6.000, suggesting confidence in future profitability and growth.

Cons of Medtronic

  • The company reported a decrease in EPS from $1.62 in the same quarter last year, which may raise concerns about declining profitability.
  • Medtronic plc's net margin stands at 13.20%, which, while positive, may be lower compared to industry peers, indicating potential challenges in cost management.
  • The dividend payout ratio is currently at 77.21%, suggesting that a significant portion of earnings is being distributed as dividends, which could limit reinvestment in growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$115.16 billion
P/E Ratio
24.47
Consensus Rating
Moderate Buy
Consensus Price Target
$99.79 (+9.3% Upside)
Volume
6.47 million shares
Average Volume
6.71 million shares
Today's Range
$89.94
$91.56
50-Day Range
$78.25
$94.13
52-Week Range
$73.31
$106.33
Dividend Yield
3.20%
Sanofi stock logo

21. Sanofi NASDAQ:SNY

$44.82 -0.02 (-0.04%)
As of 04:00 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • The current stock price is around $60, which is near its 1-year high, indicating strong market performance and investor confidence.
  • Sanofi has a low debt-to-equity ratio, suggesting a conservative approach to leverage, which can be appealing to risk-averse investors.
  • The company has a diverse portfolio across multiple therapeutic areas, including oncology and immunology, which can provide stability and growth potential.

Cons of Sanofi

  • The quick ratio is below 1, indicating potential liquidity issues, which could affect the company's ability to meet short-term obligations.
  • Despite recent growth, the stock has shown volatility, which may deter risk-averse investors looking for stable returns.
  • Sanofi operates in a highly competitive pharmaceutical market, which can impact its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$108.71 billion
P/E Ratio
23.47
Consensus Rating
Hold
Consensus Price Target
$49.50 (+10.4% Upside)
Volume
1.36 million shares
Average Volume
2.52 million shares
Today's Range
$44.65
$44.96
50-Day Range
$41.33
$46.02
52-Week Range
$40.89
$52.68
Dividend Yield
3.94%
McKesson stock logo

22. McKesson NYSE:MCK

$895.59 +5.08 (+0.57%)
As of 03:58 PM Eastern

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The company recently reported strong earnings, with earnings per share (EPS) of approximately $9.93, exceeding expectations, which indicates robust financial performance.
  • McKesson Co. has shown a year-over-year revenue growth of about 7.7%, suggesting a positive trend in its business operations and market demand.
  • The current stock price is around $820, reflecting a stable valuation in the healthcare sector, which can be attractive for long-term investors.

Cons of McKesson

  • Despite strong earnings, McKesson Co. has a negative return on equity of over 253%, which may raise concerns about its efficiency in generating profits from shareholders' equity.
  • The company has a relatively low net margin of 1.12%, indicating that a small portion of revenue is converted into profit, which could limit growth potential.
  • McKesson Co. has a beta of 0.30, suggesting lower volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$103.82 billion
P/E Ratio
23.97
Consensus Rating
Moderate Buy
Consensus Price Target
$973.44 (+8.7% Upside)
Volume
605,976 shares
Average Volume
1.02 million shares
Today's Range
$890.80
$900.22
50-Day Range
$745.12
$904.31
52-Week Range
$679.65
$999.00
Dividend Yield
0.37%
GSK stock logo

23. GSK NYSE:GSK

$50.80 +0.53 (+1.05%)
As of 03:58 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $108, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • GSK plc has a strong market capitalization of approximately $108.73 billion, indicating a solid position in the market and potential for growth.
  • The company has a dividend yield of about 3.3%, providing a steady income stream for investors, which is attractive in a low-interest-rate environment.

Cons of GSK

  • The company has a relatively high price-to-earnings (PE) ratio of 13.97, which may suggest that the stock is overvalued compared to its earnings.
  • GSK plc's price-to-earnings-growth (PEG) ratio of 3.27 indicates that the stock may not be growing fast enough to justify its current valuation, which could deter growth-focused investors.
  • Recent changes in institutional holdings show mixed signals, with some hedge funds increasing their stakes while others are making new positions, indicating uncertainty in investor sentiment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$101.68 billion
P/E Ratio
15.88
Consensus Rating
Hold
Consensus Price Target
$53.00 (+4.3% Upside)
Volume
3.43 million shares
Average Volume
3.12 million shares
Today's Range
$49.95
$50.88
50-Day Range
$49.54
$53.78
52-Week Range
$38.63
$61.69
Dividend Yield
3.53%
HCA Healthcare stock logo

24. HCA Healthcare NYSE:HCA

$417.57 -1.77 (-0.42%)
As of 03:58 PM Eastern

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The company recently reported earnings per share of $7.59, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • HCA Healthcare, Inc. has shown a year-over-year revenue increase of 8.7%, suggesting a robust business model and effective management strategies.
  • The current stock price is around $462.64, which is considered attractive given the company's growth prospects and market position.

Cons of HCA Healthcare

  • The company has a negative return on equity of 244.79%, which may raise concerns about its efficiency in generating profits from shareholders' equity.
  • Despite recent revenue growth, the stock has experienced significant price fluctuations, indicating potential volatility that could deter risk-averse investors.
  • Some analysts have downgraded their price targets for HCA Healthcare, suggesting a cautious outlook that may affect investor sentiment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$90.79 billion
P/E Ratio
13.98
Consensus Rating
Moderate Buy
Consensus Price Target
$462.64 (+10.8% Upside)
Volume
1.00 million shares
Average Volume
1.19 million shares
Today's Range
$416.52
$426.37
50-Day Range
$364.47
$429.19
52-Week Range
$353.99
$556.52
Dividend Yield
0.74%
Elevance Health stock logo

25. Elevance Health NYSE:ELV

$395.28 -3.83 (-0.96%)
As of 03:58 PM Eastern

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$86.55 billion
P/E Ratio
17.57
Consensus Rating
Moderate Buy
Consensus Price Target
$440.90 (+11.5% Upside)
Volume
561,307 shares
Average Volume
902,847 shares
Today's Range
$394.40
$403.16
50-Day Range
$372.20
$430.21
52-Week Range
$274.84
$436.24
Dividend Yield
1.72%
Regeneron Pharmaceuticals stock logo

26. Regeneron Pharmaceuticals NASDAQ:REGN

$794.19 -13.52 (-1.67%)
As of 04:00 PM Eastern

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The current stock price is around $720, which reflects a strong market position and investor confidence in the company's future growth potential.
  • Regeneron Pharmaceuticals, Inc. reported impressive quarterly earnings, significantly exceeding analysts' expectations, indicating robust financial health and operational efficiency.
  • The company has a low debt-to-equity ratio, suggesting a conservative approach to leveraging, which can be appealing to risk-averse investors.

Cons of Regeneron Pharmaceuticals

  • The stock has shown relatively low volatility, which may indicate limited growth potential compared to more aggressive biotech firms.
  • Despite recent successes, the biopharmaceutical industry is highly competitive, and Regeneron Pharmaceuticals, Inc. faces ongoing pressure from other companies developing similar therapies.
  • The company's reliance on a few key products for revenue could pose risks if market dynamics change or if new competitors emerge.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$83.16 billion
P/E Ratio
19.63
Consensus Rating
Moderate Buy
Consensus Price Target
$800.36 (+0.8% Upside)
Volume
487,735 shares
Average Volume
741,007 shares
Today's Range
$789.08
$809.40
50-Day Range
$612.50
$840.84
52-Week Range
$541.00
$847.00
Dividend Yield
0.47%
Cigna Group stock logo

27. Cigna Group NYSE:CI

$278.89 +1.22 (+0.44%)
As of 03:58 PM Eastern

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The current stock price is around $274.50, which may present a buying opportunity for investors looking for value in the health services sector.
  • The Cigna Group reported a strong quarterly earnings per share of $7.78, exceeding analysts' expectations, indicating robust financial performance.
  • The company has set a positive FY 2026 guidance with an expected earnings per share of 30.450, suggesting potential growth in profitability.

Cons of Cigna Group

  • The stock has experienced a decline of about 1.1% recently, which may indicate short-term volatility and investor uncertainty.
  • Some analysts have downgraded their ratings, with Deutsche Bank cutting their rating from Buy to Hold, suggesting caution among market experts.
  • The company has a debt-to-equity ratio of 0.68, which, while manageable, indicates that The Cigna Group has a significant amount of debt compared to its equity, potentially increasing financial risk.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$73.37 billion
P/E Ratio
11.54
Consensus Rating
Moderate Buy
Consensus Price Target
$339.45 (+21.7% Upside)
Volume
1.60 million shares
Average Volume
1.79 million shares
Today's Range
$277.65
$280.68
50-Day Range
$270.53
$304.60
52-Week Range
$239.51
$315.47
Dividend Yield
2.25%
Boston Scientific stock logo

28. Boston Scientific NYSE:BSX

$46.82 +0.15 (+0.32%)
As of 03:58 PM Eastern

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The current stock price is around $46, which may be considered attractive compared to its 1-year high of $109.50, suggesting potential for growth.
  • Boston Scientific Co. reported a strong quarterly earnings performance, with earnings per share of $0.86, exceeding analyst expectations, indicating robust financial health.
  • The company has a solid return on equity of 19.28%, reflecting effective management and profitability, which can be appealing to investors looking for strong performance metrics.

Cons of Boston Scientific

  • The company has a quick ratio of 0.74, which may indicate potential liquidity issues, as it suggests that the company might struggle to cover its short-term liabilities.
  • Despite recent revenue growth, the price-to-earnings ratio of around 20.40 could suggest that the stock is overvalued compared to its earnings, which may deter value-focused investors.
  • The beta of 0.56 indicates lower volatility compared to the market, which might not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$67.64 billion
P/E Ratio
18.96
Consensus Rating
Moderate Buy
Consensus Price Target
$71.62 (+53.0% Upside)
Volume
17.14 million shares
Average Volume
19.52 million shares
Today's Range
$46.50
$47.22
50-Day Range
$42.64
$52.02
52-Week Range
$42.20
$109.50
Dividend Yield
N/A
argenex stock logo

29. argenex NASDAQ:ARGX

$1,023.21 -35.69 (-3.37%)
As of 04:00 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The company recently reported strong earnings, with earnings per share significantly exceeding analyst expectations, indicating robust financial performance.
  • argenx SE has a high net margin, showcasing its efficiency in converting revenue into profit, which is attractive for potential investors.
  • With a market capitalization of approximately $63.78 billion, argenx SE is positioned as a major player in the biotechnology sector, suggesting stability and growth potential.

Cons of argenex

  • The stock has shown volatility, with a significant range between its one-year low and high, which may pose risks for conservative investors.
  • Despite strong earnings, the high P/E ratio suggests that the stock may be overvalued, which could lead to corrections in the future.
  • There is a substantial reliance on the success of its antibody-based therapeutics, which can be unpredictable and subject to regulatory challenges.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$66.25 billion
P/E Ratio
39.29
Consensus Rating
Moderate Buy
Consensus Price Target
$1,157.50 (+13.1% Upside)
Volume
175,513 shares
Average Volume
315,147 shares
Today's Range
$1,018.60
$1,053.00
50-Day Range
$830.79
$1,058.90
52-Week Range
$661.85
$1,061.57
Dividend Yield
N/A
Cencora stock logo

30. Cencora NYSE:COR

$322.12 +0.89 (+0.28%)
As of 03:58 PM Eastern

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is around $301, which may be considered attractive for potential investors looking for entry points in a stable company.
  • Cencora, Inc. has demonstrated strong financial performance with a return on equity of over 125%, indicating effective management and profitability relative to shareholder equity.
  • The company recently announced a significant stock repurchase plan of $2.00 billion, suggesting that the board believes the shares are undervalued, which can lead to increased shareholder value.

Cons of Cencora

  • The company has a relatively high debt-to-equity ratio of 3.53, which may raise concerns about financial stability and the ability to manage debt effectively.
  • With a net margin of only 0.79%, Cencora, Inc. operates on thin profit margins, which could limit its ability to weather economic downturns or increased competition.
  • The stock has shown volatility, with a beta of 0.57, indicating that it may not be as stable as some investors prefer, potentially leading to unpredictable price movements.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$61.30 billion
P/E Ratio
23.93
Consensus Rating
Moderate Buy
Consensus Price Target
$370.85 (+15.1% Upside)
Volume
628,845 shares
Average Volume
1.48 million shares
Today's Range
$320.39
$323.74
50-Day Range
$271.14
$333.21
52-Week Range
$244.82
$377.54
Dividend Yield
0.75%
Takeda Pharmaceutical stock logo

31. Takeda Pharmaceutical NYSE:TAK

$18.03 0.00 (0.00%)
As of 03:58 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The company reported earnings per share of $0.47 for the latest quarter, significantly exceeding analysts' expectations of $0.17, indicating strong financial performance.
  • With a revenue of $7.50 billion for the quarter, surpassing the forecast of $7.13 billion, Takeda Pharmaceutical Company Limited demonstrates robust sales growth.
  • The current stock price is around $17.10, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.

Cons of Takeda Pharmaceutical

  • Recent insider selling, including significant transactions by executives, may raise concerns about the company's future prospects and management confidence.
  • Takeda Pharmaceutical Company Limited has a net margin of 3.80%, which is relatively low compared to industry standards, indicating potential challenges in profitability.
  • Some analysts have downgraded the stock rating, with one brokerage moving from a "hold" to a "sell" rating, reflecting cautious sentiment in the market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$57.77 billion
P/E Ratio
53.03
Consensus Rating
Hold
Consensus Price Target
N/A
Volume
1.81 million shares
Average Volume
3.05 million shares
Today's Range
$17.96
$18.11
50-Day Range
$15.46
$18.37
52-Week Range
$12.99
$18.90
Dividend Yield
2.67%
Moderna stock logo

32. Moderna NASDAQ:MRNA

$137.99 -4.78 (-3.35%)
As of 04:00 PM Eastern

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. More about Moderna

Pros of Moderna

  • The recent approval of Moderna's first mRNA-based seasonal influenza vaccine, mFLUSIVA, highlights the company's innovative approach and potential for future product development in the vaccine market.
  • Moderna's recent Phase 3 trial for its individualized mRNA neoantigen therapy showed positive results, indicating a significant advancement in personalized cancer treatment, which could open new revenue streams.
  • The current stock price is around $64.91, which may present a buying opportunity for investors looking to capitalize on potential future growth as the company expands its product offerings.

Cons of Moderna

  • Moderna reported a negative net margin, indicating that the company is currently spending more than it earns, which could raise concerns about its financial sustainability.
  • The company has a negative return on equity, suggesting that it is not effectively generating profits from its shareholders' investments, which may deter potential investors.
  • Recent insider selling activity may raise red flags for investors, as it could indicate a lack of confidence from those within the company regarding its future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$57.00 billion
P/E Ratio
N/A
Consensus Rating
Hold
Consensus Price Target
$80.53 (-41.6% Downside)
Volume
25.76 million shares
Average Volume
29.45 million shares
Today's Range
$133.33
$138.80
50-Day Range
$53.86
$174.38
52-Week Range
$22.28
$176.66
Dividend Yield
N/A
Cardinal Health stock logo

33. Cardinal Health NYSE:CAH

$234.72 -0.41 (-0.17%)
As of 03:58 PM Eastern

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • Cardinal Health, Inc. has reported a revenue increase of approximately 5.8% compared to the same quarter last year, indicating strong growth potential.
  • The company has set its fiscal year 2027 earnings per share (EPS) guidance between $12.40 and $12.60, aligning well with analyst expectations, which suggests stability and confidence in future performance.
  • Recent quarterly results showed that earnings per share exceeded consensus estimates, reflecting effective management and operational efficiency.

Cons of Cardinal Health

  • The dividend yield is relatively low at around 0.9%, which may not attract income-focused investors looking for higher returns from dividends.
  • Despite recent growth, the company operates in a highly competitive healthcare market, which could impact its market share and profitability in the long term.
  • Cardinal Health, Inc. has a dividend payout ratio of 28.49%, which, while sustainable, may limit the company’s ability to reinvest in growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$54.69 billion
P/E Ratio
32.46
Consensus Rating
Moderate Buy
Consensus Price Target
$266.56 (+13.6% Upside)
Volume
1.78 million shares
Average Volume
1.87 million shares
Today's Range
$233.72
$236.80
50-Day Range
$221.09
$240.08
52-Week Range
$145.87
$258.30
Dividend Yield
0.88%
Becton, Dickinson and Company stock logo

34. Becton, Dickinson and Company NYSE:BDX

$189.71 +1.58 (+0.84%)
As of 03:58 PM Eastern

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The company recently reported a quarterly revenue increase of 5.4% compared to the same quarter last year, indicating strong growth potential.
  • Becton, Dickinson and Company has set its FY 2026 guidance at an EPS range of 12.620-12.720, suggesting confidence in future earnings performance.
  • The current stock price is around $182, which is near its 52-week high, reflecting positive market sentiment.

Cons of Becton, Dickinson and Company

  • The company's dividend payout ratio is quite high at 126.51%, which may raise concerns about sustainability in the long term.
  • Insider selling has been observed, with executives reducing their positions, which could signal a lack of confidence in the company's near-term prospects.
  • The stock has a high P/E ratio of 54.94, suggesting that it may be overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$51.84 billion
P/E Ratio
57.14
Consensus Rating
Hold
Consensus Price Target
$185.67 (-2.1% Downside)
Volume
1.69 million shares
Average Volume
1.82 million shares
Today's Range
$187.54
$190.32
50-Day Range
$140.37
$191.95
52-Week Range
$127.59
$193.07
Dividend Yield
2.23%
Edwards Lifesciences stock logo

35. Edwards Lifesciences NYSE:EW

$90.19 +0.24 (+0.27%)
As of 03:58 PM Eastern

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The current stock price is around $89, which is near its 50-day moving average, indicating potential stability in the short term.
  • Edwards Lifesciences Co. reported a significant increase in revenue, up 13.6% compared to the same quarter last year, showcasing strong growth potential.
  • The company has a low debt-to-equity ratio, suggesting a strong balance sheet and lower financial risk, which can be attractive to investors.

Cons of Edwards Lifesciences

  • The price-to-earnings ratio is relatively high at 52.26, which may indicate that the stock is overvalued compared to its earnings.
  • Despite recent revenue growth, the company has set conservative earnings guidance for Q3 2026, which may signal caution about future performance.
  • Insider selling activity has been noted, with executives selling shares, which could raise concerns about their confidence in the company's future prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$51.79 billion
P/E Ratio
51.83
Consensus Rating
Moderate Buy
Consensus Price Target
$100.27 (+11.2% Upside)
Volume
2.04 million shares
Average Volume
3.07 million shares
Today's Range
$89.55
$90.41
50-Day Range
$82.67
$95.17
52-Week Range
$72.30
$96.29
Dividend Yield
N/A
Natera stock logo

36. Natera NASDAQ:NTRA

$326.26 -12.44 (-3.67%)
As of 04:00 PM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Market Capitalization
$48.82 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$319.38 (-2.1% Downside)
Volume
833,644 shares
Average Volume
1.50 million shares
Today's Range
$325.66
$339.30
50-Day Range
$228.80
$338.70
52-Week Range
$157.43
$343.18
Dividend Yield
N/A
Revolution Medicines stock logo

37. Revolution Medicines NASDAQ:RVMD

$207.88 -13.27 (-6.00%)
As of 04:00 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Market Capitalization
$47.40 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$198.89 (-4.3% Downside)
Volume
2.00 million shares
Average Volume
1.80 million shares
Today's Range
$205.82
$221.50
50-Day Range
$165.81
$221.15
52-Week Range
$37.56
$224.31
Dividend Yield
N/A
Humana stock logo

38. Humana NYSE:HUM

$386.92 -5.71 (-1.45%)
As of 03:58 PM Eastern

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The company reported strong earnings per share (EPS) of $7.61 for the latest quarter, exceeding expectations, which indicates robust financial performance and potential for future growth.
  • Humana Inc. experienced a significant year-over-year revenue increase of 26.2%, showcasing its ability to expand and capture market share effectively.
  • With a current stock price around $395, the stock has been rated positively by a majority of analysts, with many giving it a "Buy" rating, suggesting confidence in its future performance.

Cons of Humana

  • The company has a relatively low net margin of 0.88%, which may indicate challenges in controlling costs and maximizing profitability compared to competitors.
  • Despite positive growth, the stock has been subject to varying target price adjustments by analysts, reflecting uncertainty in its valuation and potential volatility.
  • Humana Inc. has received a "Sell" rating from some analysts, which could signal potential risks or concerns about its future performance in the market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$47.15 billion
P/E Ratio
36.61
Consensus Rating
Hold
Consensus Price Target
$403.91 (+4.4% Upside)
Volume
746,547 shares
Average Volume
1.13 million shares
Today's Range
$385.22
$397.33
50-Day Range
$359.99
$409.92
52-Week Range
$163.11
$428.88
Dividend Yield
0.90%
Veeva Systems stock logo

39. Veeva Systems NYSE:VEEV

$277.27 -4.86 (-1.72%)
As of 03:58 PM Eastern

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • The company recently reported earnings per share of $2.35, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • Veeva Systems Inc. achieved a revenue of approximately $928 million for the quarter, surpassing estimates, showcasing its robust market demand and operational efficiency.
  • The firm has a solid net margin of over 28%, reflecting its ability to convert revenue into profit effectively, which is a positive indicator for investors.

Cons of Veeva Systems

  • Analysts have recently adjusted their price targets downward, with some firms reducing their expectations significantly, which may indicate a lack of confidence in future growth.
  • Despite strong earnings, the stock has faced pressure from market analysts, with several rating it as a "hold" or "sell," suggesting caution among investors.
  • The company’s guidance for FY 2027 shows a modest growth expectation, which may not excite investors looking for aggressive growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.83 billion
P/E Ratio
45.60
Consensus Rating
Moderate Buy
Consensus Price Target
$284.46 (+2.6% Upside)
Volume
3.64 million shares
Average Volume
1.97 million shares
Today's Range
$276.45
$284.68
50-Day Range
$153.20
$282.76
52-Week Range
$148.05
$310.50
Dividend Yield
N/A
Medline stock logo

40. Medline NASDAQ:MDLN

$35.28 +0.63 (+1.82%)
As of 04:00 PM Eastern

Our mission is to make healthcare run better by delivering improved clinical, financial, and operational outcomes. We are the largest provider of medical-surgical (“med-surg”) products and supply chain solutions serving all points of care, based on total net sales of med-surg products. We deliver mission-critical products used daily across the full range of care settings, from hospitals and surgery centers to physician offices and post-acute facilities. Through our two segments, Medline Brand and Supply Chain Solutions, we offer approximately 335,000 med-surg products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products. We hold the leading position across several of our end markets and many of our key product families. We distribute these products through our expansive network of 69 global distribution facilities, spanning over 29 million square feet of warehouse space, and our owned fleet of over 2,000 MedTrans trucks, enabling us to provide next-day delivery to 95% of our U.S. customers. Our integrated business model and customer-centric culture drives lower costs and better value for our stakeholders. This is the foundation for our durable recurring revenue base, with our net sales having grown every year since inception of the Company at a compound annual growth rate (“CAGR”) of 18%. --- We were founded in 1966 as a med-surg product manufacturer serving the hospital and nursing home sites of care. Through our deep engagement with customers, we recognized a significant gap in the market—our customers were underserved by a fragmented supplier base and faced challenges navigating a complex supply chain. We identified their need for a supply chain partner that was fully integrated, cost-effective, high-quality, and resilient. Our vision was to create a differentiated model that solved these pain points through an integrated company that combined both manufacturing and distribution capabilities and would become a trusted partner to our customers. Twenty-eight years ago, we began augmenting our platform to bring this vision to life: we invested in our distribution capabilities, continued to expand our product portfolio, and adopted the Prime Vendor model. This enabled us to serve a more diverse customer base across multiple end markets, while lowering costs and delivering superior service levels. As a result, Medline is now the largest provider of med-surg products and supply chain solutions serving all points of care, based on total net sales of med-surg products. The combination of our expansive product portfolio and our differentiated supply chain creates a force multiplier for our business. Our Medline Brand segment offers approximately 190,000 products, including those manufactured in our 33 facilities, as well as those sourced from our more than 500 global partners. Our Supply Chain Solutions segment offers approximately 145,000 third-party products and provides customized supply chain optimization services. Our entire product portfolio across our segments is supported by differentiated logistics capabilities and a dedicated and tenured U.S. commercial team of approximately 3,800 people. These capabilities and our compelling value proposition allow us to serve as a long-term strategic partner to our customers and expand the scope of our relationships over time. Our Prime Vendor relationships demonstrate our role as a trusted partner to our customers. In these relationships, we enter into long-term agreements to act as the consolidated distributor and logistics provider for these customers’ med-surg product needs. These partnerships give us visibility into our customers’ purchasing behaviors and demand dynamics, which allows us to anticipate their needs and deliver industry-leading service levels. As these relationships mature, we believe customers increasingly choose Medline Brand products for their superior value. Our Prime Vendor model is reinforced by the flywheel effect within our business where we drive cost savings for Prime Vendor customers, which, over time, supports incremental purchasing of our Medline Brand products and increases our scale. This dynamic allows us to drive further efficiencies by offering superior or similar quality to third-party products at a more cost-effective price. Due to the higher margin we earn on Medline Brand products compared to sales of comparable third-party products, we are able to reinvest in customer value while increasing our profitability. --- Since our founding, we have invested in building a unique customer-centric culture with an entrepreneurial spirit. Our employees are committed to deeply understanding how our customers operate, what challenges they face, and how Medline can better support them. They also understand that relationships are rooted in trust and that we must earn the right to serve our customers every day. We focus on problem solving across the continuum of care and we deploy a team of dedicated customer success representatives to learn the complex needs of our customers. Our creative and collaborative culture consistently earns Medline recognition as a preferred employer, including Newsweek’s Greatest Workplaces, Forbes’ America’s Best Large Employers, and a Chicago Tribune Top Workplace. We have grown our net sales every year by retaining existing customers while gaining share with new and existing customers, with CAGRs of 18% since our founding and approximately 14% over the past 10 years. Notably, nearly 90% of our growth during the past 10 years has been organic. Our product portfolio predominantly consists of consumables, such that approximately 90% of our Medline Brand net sales were recurring for the year ended December 31, 2024. Our business is uniquely resilient during market downturns, as evidenced by our growth through every recession since our founding and during global healthcare crises. For example, our net sales grew at approximately 17% during the 2008-2009 financial crisis and at approximately 11% CAGR during the 2020-2022 COVID-19 pandemic. Not only does our business have a strong track record of results, but we also see significant runway for future sales and earnings growth. We are positioned to grow with our customers as healthcare utilization increases, as they build and acquire new sites, and as they further consolidate med-surg spend with Medline. In addition, we intend to further extend our leading position by adding new Prime Vendor relationships, increasing the number of non-Prime Vendor customers that choose Medline Brand, continuing our channel expansion, developing new products, executing on selective M&A opportunities, and scaling our international footprint. For the nine months ended September 27, 2025, we generated net sales of $20.6 billion, net income of $1.0 billion, and Adjusted EBITDA of $2.7 billion, representing a net income margin of 4.7% and an Adjusted EBITDA Margin of 12.9%. During that period, 48.4% of total net sales and 81.2% of Segment Adjusted EBITDA were generated from our Medline Brand segment, while 51.6% of total net sales and 18.8% of Segment Adjusted EBITDA were generated from our Supply Chain Solutions segment. For the year ended December 31, 2024, we generated net sales of $25.5 billion, net income of $1.2 billion, and Adjusted EBITDA of $3.4 billion, representing a net income margin of 4.7% and an Adjusted EBITDA Margin of 13.2%. During that period, 49.1% of total net sales and 83.5% of Segment Adjusted EBITDA were generated from our Medline Brand segment, while 50.9% of total net sales and 16.5% of Segment Adjusted EBITDA were generated from our Supply Chain Solutions segment. Our principal executive offices are located in Northfield, Illinois.

Market Capitalization
$45.55 billion
P/E Ratio
44.66
Consensus Rating
Moderate Buy
Consensus Price Target
$47.42 (+34.4% Upside)
Volume
5.71 million shares
Average Volume
7.92 million shares
Today's Range
$34.60
$35.77
50-Day Range
$32.58
$43.19
52-Week Range
$32.49
$50.88
Dividend Yield
N/A
Agilent Technologies stock logo

41. Agilent Technologies NYSE:A

$154.47 -3.22 (-2.04%)
As of 03:58 PM Eastern

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • Agilent Technologies, Inc. reported strong quarterly earnings, with earnings per share (EPS) of $1.62, exceeding expectations and indicating robust financial health.
  • The company achieved a revenue of $1.88 billion, which is an 8.1% increase year-over-year, showcasing its growth potential in the market.
  • Agilent Technologies, Inc. has a solid net margin of approximately 19.5%, reflecting effective cost management and profitability.

Cons of Agilent Technologies

  • The stock has a relatively high price-to-earnings (P/E) ratio of about 31.63, which may suggest that it is overvalued compared to its earnings.
  • Despite recent growth, the company faces significant competition in the scientific instrumentation market, which could impact future revenue growth.
  • Agilent Technologies, Inc. has a beta of 1.25, indicating that its stock price is more volatile than the market, which could pose risks for conservative investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.54 billion
P/E Ratio
30.41
Consensus Rating
Moderate Buy
Consensus Price Target
$170.33 (+10.3% Upside)
Volume
2.97 million shares
Average Volume
1.98 million shares
Today's Range
$152.77
$156.10
50-Day Range
$126.34
$159.25
52-Week Range
$108.35
$163.75
Dividend Yield
0.65%
Teva Pharmaceutical Industries stock logo

42. Teva Pharmaceutical Industries NYSE:TEVA

$36.45 -1.17 (-3.11%)
As of 03:58 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Market Capitalization
$43.84 billion
P/E Ratio
60.75
Consensus Rating
Moderate Buy
Consensus Price Target
$42.22 (+15.8% Upside)
Volume
3.14 million shares
Average Volume
5.16 million shares
Today's Range
$36.37
$37.42
50-Day Range
$30.19
$38.02
52-Week Range
$17.94
$38.37
Dividend Yield
N/A
IQVIA stock logo

43. IQVIA NYSE:IQV

$260.48 -1.90 (-0.72%)
As of 03:58 PM Eastern

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • IQVIA Holdings Inc. reported earnings per share (EPS) of $3.15 for the latest quarter, surpassing expectations, which indicates strong financial performance and potential for growth.
  • The company has a robust return on equity of 30.25%, suggesting effective management and the ability to generate profits from shareholders' investments.
  • With a net margin of 8.10%, IQVIA Holdings Inc. demonstrates efficiency in converting revenue into profit, which is attractive for investors looking for stable returns.

Cons of IQVIA

  • Insider selling has been observed, with significant shares sold recently, which may raise concerns about the confidence of those closest to the company in its future performance.
  • Despite strong earnings, the company operates in a highly competitive market, which could impact its ability to maintain growth and profitability in the long term.
  • High institutional ownership, at 89.62%, may lead to volatility in stock price as large investors can significantly influence market movements.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.19 billion
P/E Ratio
32.32
Consensus Rating
Moderate Buy
Consensus Price Target
$241.88 (-7.1% Downside)
Volume
1.84 million shares
Average Volume
1.23 million shares
Today's Range
$258.08
$262.82
50-Day Range
$167.83
$262.18
52-Week Range
$154.50
$265.25
Dividend Yield
N/A
IDEXX Laboratories stock logo

44. IDEXX Laboratories NASDAQ:IDXX

$554.99 +9.91 (+1.82%)
As of 04:00 PM Eastern

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price is around $720, which reflects a strong market position and investor confidence in the company's growth potential.
  • IDEXX Laboratories, Inc. reported a significant year-over-year revenue increase of nearly 10%, indicating robust demand for its diagnostic products and services.
  • The company has a high return on equity, showcasing its efficiency in generating profits from shareholders' equity, which is appealing to investors looking for strong financial performance.

Cons of IDEXX Laboratories

  • The company has a relatively high price-to-earnings (P/E) ratio, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • IDEXX Laboratories, Inc. has a quick ratio below 1, suggesting that it may struggle to meet its short-term liabilities with its most liquid assets, which could raise concerns about liquidity.
  • Despite recent revenue growth, the company's earnings per share (EPS) growth may not keep pace with its high valuation, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$42.94 billion
P/E Ratio
39.03
Consensus Rating
Moderate Buy
Consensus Price Target
$747.00 (+34.6% Upside)
Volume
340,976 shares
Average Volume
623,152 shares
Today's Range
$545.48
$556.01
50-Day Range
$526.44
$595.76
52-Week Range
$518.55
$769.98
Dividend Yield
N/A
Waters stock logo

45. Waters NYSE:WAT

$414.55 -6.71 (-1.59%)
As of 03:58 PM Eastern

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Market Capitalization
$41.39 billion
P/E Ratio
103.38
Consensus Rating
Moderate Buy
Consensus Price Target
$424.35 (+2.4% Upside)
Volume
435,135 shares
Average Volume
848,192 shares
Today's Range
$412.38
$422.50
50-Day Range
$356.82
$420.35
52-Week Range
$282.77
$426.22
Dividend Yield
N/A
BeOne Medicines stock logo

46. BeOne Medicines NASDAQ:ONC

$366.73 -5.76 (-1.55%)
As of 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$40.89 billion
P/E Ratio
64.57
Consensus Rating
Buy
Consensus Price Target
$402.14 (+9.7% Upside)
Volume
341,579 shares
Average Volume
401,641 shares
Today's Range
$364.73
$372.00
50-Day Range
$271.80
$376.86
52-Week Range
$253.95
$385.22
Dividend Yield
N/A
Alcon stock logo

47. Alcon NYSE:ALC

$72.01 -0.22 (-0.30%)
As of 03:58 PM Eastern

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is around $79.18, reflecting a strong market position and potential for growth.
  • Alcon Inc. has shown a consistent average daily trading volume, indicating active investor interest and liquidity in the stock.
  • Recent short interest data suggests a relatively low short percentage of float, which may indicate investor confidence in the company's performance.

Cons of Alcon

  • The company has a relatively high number of shares shorted, which could indicate that some investors are betting against its performance.
  • There has been a slight increase in the month-to-month change percentage of shares shorted, suggesting growing skepticism among some market participants.
  • Alcon Inc. has reported zero institutional ownership, which may raise concerns about the company's appeal to larger, more stable investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$35.73 billion
P/E Ratio
54.97
Consensus Rating
Moderate Buy
Consensus Price Target
$84.96 (+18.0% Upside)
Volume
1.18 million shares
Average Volume
1.75 million shares
Today's Range
$71.38
$72.07
50-Day Range
$65.15
$75.25
52-Week Range
$61.83
$87.64
Dividend Yield
N/A
Royalty Pharma stock logo

48. Royalty Pharma NASDAQ:RPRX

$60.85 -1.07 (-1.73%)
As of 04:00 PM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. More about Royalty Pharma

Pros of Royalty Pharma

  • The current stock price is around $56, which reflects a strong performance compared to its 12-month low of $34.08 and high of $60.44, indicating potential for growth.
  • Royalty Pharma plc has a solid return on equity of over 30%, suggesting effective management and profitability, which can be attractive to investors looking for strong financial performance.
  • The company recently reported earnings that exceeded expectations, showcasing its ability to generate revenue and manage costs effectively, which can lead to increased investor confidence.

Cons of Royalty Pharma

  • The company reported revenue that fell short of analysts' expectations, which may raise concerns about its growth prospects and ability to meet future targets.
  • Royalty Pharma plc has a relatively high price-to-earnings ratio, indicating that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • With a debt-to-equity ratio of 0.88, the company carries a significant amount of debt, which could pose risks in times of economic downturns or rising interest rates.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$35.60 billion
P/E Ratio
41.97
Consensus Rating
Buy
Consensus Price Target
$60.86 (+0.0% Upside)
Volume
1.70 million shares
Average Volume
2.71 million shares
Today's Range
$60.66
$62.01
50-Day Range
$53.57
$62.07
52-Week Range
$34.08
$62.46
Dividend Yield
1.52%
Illumina stock logo

49. Illumina NASDAQ:ILMN

$215.59 -12.10 (-5.31%)
As of 04:00 PM Eastern

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. More about Illumina

Pros of Illumina

  • Illumina, Inc. has demonstrated strong revenue growth, with a recent quarterly revenue increase of 9.4% year-over-year, indicating robust demand for its products and services.
  • The company has set its fiscal year 2026 guidance at an earnings per share (EPS) range of 5.300-5.400, suggesting confidence in future profitability.
  • Illumina, Inc. reported earnings per share of $1.31 for the last quarter, surpassing analysts' expectations, which reflects strong operational performance.

Cons of Illumina

  • Insider selling has been notable, with significant shares sold recently, which may raise concerns about the company's future prospects from those closest to it.
  • The stock has a relatively high price-to-earnings (P/E) ratio of 35.61, which could indicate that it is overvalued compared to its earnings, making it a riskier investment.
  • Illumina, Inc. has a beta of 1.44, suggesting that its stock price is more volatile than the market, which could lead to larger price swings and increased risk for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.38 billion
P/E Ratio
40.22
Consensus Rating
Hold
Consensus Price Target
$188.40 (-12.6% Downside)
Volume
1.79 million shares
Average Volume
2.07 million shares
Today's Range
$214.61
$225.10
50-Day Range
$161.38
$227.69
52-Week Range
$88.00
$231.81
Dividend Yield
N/A
ResMed stock logo

50. ResMed NYSE:RMD

$240.47 +4.71 (+2.00%)
As of 03:58 PM Eastern

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • The current stock price is around $293, reflecting a strong performance over the past year.
  • ResMed Inc. reported a significant increase in quarterly revenue, up 8.6% year-over-year, indicating robust demand for its products.
  • The company has a solid return on equity of 25.58%, showcasing effective management and profitability.

Cons of ResMed

  • Despite recent revenue growth, the company's earnings per share (EPS) growth may not keep pace with market expectations, with analysts predicting an EPS of 12.03 for the current fiscal year.
  • The dividend payout ratio is relatively low at 23.01%, which may indicate that the company is retaining a significant portion of its earnings for reinvestment rather than returning to shareholders.
  • Market competition in the medical device sector is intensifying, which could impact ResMed Inc.'s market share and pricing power.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.01 billion
P/E Ratio
23.06
Consensus Rating
Hold
Consensus Price Target
$239.38 (-0.5% Downside)
Volume
1.39 million shares
Average Volume
1.57 million shares
Today's Range
$235.01
$241.06
50-Day Range
$188.52
$240.47
52-Week Range
$180.26
$284.87
Dividend Yield
1.12%